Daytona Street Capital LLC Takes Position in Cencora, Inc. $COR
Daytona Street Capital LLC has acquired 40,000 shares of Cencora, Inc. (NYSE:COR) during the fourth quarter, making it their largest holding at roughly 9.0% of their investment portfolio. This move values their stake at approximately $13.51 million. Cencora recently reported earnings per share that beat analyst expectations, though revenue slightly missed estimates, and maintains a "Moderate Buy" consensus rating among analysts.
Daytona Street Capital LLC Invests $2.69 Million in CVS Health Corporation $CVS
Daytona Street Capital LLC has acquired a new position of 33,888 shares in CVS Health Corporation, valued at approximately $2.69 million, making it their 16th largest holding. This investment comes as CVS reported strong Q4 results, exceeding EPS and revenue estimates, and announced a quarterly dividend of $0.665. Analysts maintain a "Moderate Buy" rating for CVS with an average target price of $94.95.
CVS Pharmacy: Essential Retail for Health and Wellness Needs
CVS Pharmacy is an essential retail healthcare provider offering a wide range of prescription drugs, over-the-counter medications, health products, and convenience items. It integrates healthcare into daily shopping routines, providing accessibility, affordability, and critical support for chronic disease management and wellness. The company leverages technology, stringent quality standards, and digital engagement to maintain its market position against competitors and global influences.
Citizens initiates Avalo Therapeutics stock with outperform rating
Citizens initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX) with a Market Outperform rating and a $52.00 price target, citing the company's development of abdakibart for inflammatory diseases. The firm anticipates results from the Phase 2 LOTUS study in Q2 2026, which they view as a transformational catalyst, projecting peak U.S. sales of approximately $2.5 billion by 2035 for abdakibart. Other analysts like H.C. Wainwright, BTIG, Guggenheim, and TD Cowen also maintain positive ratings and price targets, expressing confidence in Avalo's pipeline.
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 101.6% in the fourth quarter, bringing its total holdings to 1,605,984 shares valued at approximately $29.34 million. This move highlights strong institutional interest, with 99.41% of the company's shares owned by institutional investors. Despite recent EPS misses and negative profitability, the stock maintains an average "Buy" rating from analysts with a mean target price of $32.20.
CVS Pharmacy: Essential Retail for Health and Wellness Needs
CVS Pharmacy serves as a crucial retail healthcare provider, offering a wide array of prescription medications, over-the-counter products, and health services globally through both physical stores and digital platforms. It integrates technology for efficiency, emphasizes product quality and variety, and maintains strict regulatory compliance. Operating under CVS Health Corporation, CVS Pharmacy is expanding its services with health hubs and personalized medicine, aiming to adapt to evolving consumer needs and market trends.
AbbVie Inc. $ABBV Shares Purchased by JB Capital LLC
JB Capital LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 269.7% in Q4, owning 16,913 shares valued at $3.86 million. AbbVie reported strong Q4 earnings, beating analyst estimates with $2.71 EPS and $16.62 billion in revenue, and issued positive FY2026 guidance. The company declared a quarterly dividend of $1.73 per share, representing an annualized yield of 3.3%.
JPMorgan Chase & Co. Makes New $3.60 Million Investment in YHN Acquisition I Limited $YHNA
JPMorgan Chase & Co. has made a new $3.60 million investment in YHN Acquisition I Limited (NASDAQ: YHNA) by purchasing 344,106 shares, representing a 4.32% ownership stake. This move indicates new institutional interest, also reflected by Berkley W R Corp increasing its position in the SPAC. Despite the investment, YHN Acquisition I, a blank-check company with no operating business, has an average "Sell" rating from analysts.
FXH Stock News Today | Earnings, Events & Price Alerts
This page provides current news and events related to FXH stock, including recent headlines from various financial news sources. It covers topics such as healthcare insurance expenses, ETF movements, insider buying, market calls, regulatory actions, and technical analysis regarding moving average levels. The platform also offers tools and resources for stock analysis and trading.
DGX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event updates for Quest Diagnostics (DGX), including their upcoming Q1 2026 financial results announcement and the launch of an AI companion for lab data analysis. It also highlights leadership appointments, dividend increases, and stock performance milestones for the company.
Check Your Medicine Cabinet: 3 Million Eye Drop Bottles Recalled at Walgreens and Kroger
K.C. Pharmaceuticals is voluntarily recalling over 3 million bottles of eye drops sold at major retailers like Walgreens and Kroger due to concerns about sterility. The FDA classified this as a Class II recall, meaning the products may not meet sterility standards, which could potentially lead to temporary or reversible health problems. The recall includes eight different eye drop products, identifiable by their UPC or NDC numbers.
⚠️ HEALTH WARNING: The recall includes products sold at major retailers like Walgreens and CVS.
A health warning has been issued regarding a recall of over 3 million bottles of eye drops. The recalled products were sold under various brands and at major retailers including Walgreens, CVS, Meijer, H-E-B, Kroger, and Rite Aid. Consumers are advised to check if they have any of the affected eye drops.
Quest Diagnostics (DGX) director defers pay into 198 phantom stock units
Timothy C. Wentworth, a director at Quest Diagnostics (DGX), has deferred his cash compensation and received 198 phantom stock units. These units, which derive from the company's Deferred Compensation Plan for Directors, will be paid out in cash when his service as a director concludes. This transaction, categorized as a grant/award acquisition, is part of his compensation rather than a direct stock purchase.
Dick’s Sporting Goods location CUT from mall - shoppers slam 'uncaring' owners
A Dick's Sporting Goods store in Pennsylvania's Beaver Valley Mall is closing on April 25 after nearly two decades, drawing sadness and anger from locals. Shoppers are criticizing the mall's owners for perceived neglect, leading to its deterioration. This closure is part of a larger "retail apocalypse" impacting brick-and-mortar stores, with many major retailers also shutting down locations.
CVS Pharmacy's Digital Health Innovations Drive Strategic Growth in North American Retail Pharmacy S
CVS Pharmacy is solidifying its leadership in the North American retail pharmacy sector through significant digital health innovations and expanded clinical services, including enhanced app-based prescription management, MinuteClinic virtual care, and AI integration. These strategic moves position CVS for continued growth by meeting evolving consumer demands for convenient and affordable healthcare. The company's resilience, driven by integrated care models and robust market share gains, makes it an attractive option for investors seeking stable revenue streams in the healthcare sector.
SPAR Group, Inc. (NASDAQ:SGRP) Q4 2025 Earnings Call Transcript
SPAR Group, Inc. (NASDAQ:SGRP) released its Q4 and full-year 2025 earnings, reporting a net loss of $24.6 million or $1.04 per diluted share, missing earnings expectations. The company emphasized its transformation in 2025 by divesting international joint ventures to focus on the U.S. and Canada markets, rebuilding its leadership, and forming a strategic partnership with ReposiTrak to enhance retail execution through AI and data. For fiscal year 2026, SPAR Group anticipates revenues between $143 million and $151 million with improved gross margins driven by a shift towards higher-margin merchandising work.
Synergy CHC Corp. (NASDAQ: SNYR) details FOCUSfactor, Flat Tummy and growth strategy
Synergy CHC Corp. (SNYR) has filed its annual report, outlining its focus on consumer health, beauty, and lifestyle products, primarily through its FOCUSfactor brain-health supplements and Flat Tummy weight-management brands. The company emphasizes an asset-light model, leveraging major retailers like Costco and Amazon, and details growth strategies including expanding into ready-to-drink beverages, new product SKUs, increased advertising, and international market penetration into Canada, Mexico, and planned entries into Asia and Australia. Key risks identified include high customer concentration, intense market competition, regulatory challenges, supply chain dependencies, and material weaknesses in internal control over financial reporting.
[DFAN14A] INGLES MARKETS INC SEC Filing
Summer Road LLC, a beneficial owner of approximately 3% of Ingles Markets Class A common stock, has filed a definitive proxy statement to elect an independent director, Rory A. Held, at the annual meeting on April 30, 2026. The firm argues that Ingles Markets' dual-class structure and Chairman Robert P. Ingle's influence have led to weak shareholder returns compared to the S&P 500 and grocery peers. Summer Road urges Class A shareholders, who collectively own nearly 77% of outstanding equity, to elect Held to improve accountability and address issues like capital allocation, executive compensation, and transparency.
Systane Eye Drops: Alcon's Leading Dry Eye Relief Product Driving Steady Growth in North American Ophthalmic Market
Alcon's Systane eye drops continue to dominate the North American dry eye treatment market, driven by increasing screen time and environmental factors. The product's clinically proven formulations, strong market share, and continuous innovation contribute to reliable revenue streams for Alcon. Systane's strategic importance in the ophthalmic sector is highlighted by its consistent sales performance, strong investor confidence, and plans for future line extensions and market expansion.
Brookstone Capital Management Increases Stake in McKesson Corporation $MCK
Brookstone Capital Management raised its stake in McKesson Corporation by 18.8% in Q4, now owning 13,821 shares valued at $11.34 million. McKesson exceeded Q4 earnings expectations with an EPS of $9.34 and revenues of $106.16 billion, also providing strong FY2026 EPS guidance. Despite some insider selling, institutional investors own 85.07% of the stock, and analysts maintain a "Moderate Buy" rating for the company.
FitLife Brands (NASDAQ: FTLF) adds Irwin Naturals in $42.5M debt-funded acquisition
FitLife Brands (NASDAQ: FTLF) has acquired Irwin Naturals for $42.5 million, a debt-funded acquisition that significantly expands its brand portfolio and wholesale reach. The deal, detailed in its recent 10-K filing, was primarily financed by a new term loan and revolving credit facility, leading to a substantial increase in FitLife's total debt to $44.7 million. While the acquisition drives revenue growth, it also highlights FitLife's high reliance on Amazon and key wholesale partners, with 49% of 2025 sales through Amazon and 14% via GNC.
Kimberly-Clark Welcomes Francesco Tinto as Chief Information & GBS Officer
Kimberly-Clark Corporation has appointed Francesco Tinto as its Chief Information and Global Business Services (GBS) Officer, where he will lead IT and GBS organizations. Tinto brings over 30 years of experience, including digital transformation roles at Walgreens Boots Alliance and Kraft Heinz, and will report to Russ Torres, President and COO. This strategic hire aims to strengthen Kimberly-Clark's "Powering Care" strategy through enhanced technological and operational capabilities.
Allspring Global Investments Holdings LLC Sells 40,638 Shares of Cencora, Inc. $COR
Allspring Global Investments Holdings LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 9.6% in the fourth quarter, selling 40,638 shares and now holding 383,068 shares valued at approximately $129.8 million. Cencora reported strong Q4 EPS of $4.08 on $85.93 billion in revenue, exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts with a mean price target of $403.17, and also recently declared a quarterly dividend of $0.60 per share.
Donaldson Capital Management LLC Has $46.31 Million Stock Holdings in Cencora, Inc. $COR
Donaldson Capital Management LLC significantly increased its stake in Cencora (NYSE:COR) by 1,955.8% in Q4, holding 137,099 shares valued at $46.31 million. Institutional investors collectively own about 97.52% of Cencora's stock. Analysts generally rate Cencora as a "Moderate Buy" with an average target price of $403.17, following a recent EPS beat and a quarterly dividend announcement.
Realty Income Dividend Analysis: Yield, Cost, and Portfolio Fit | 2026 - News and Statistics
Realty Income, a real estate investment trust, is highlighted as a strong dividend stock for income-focused investors, offering a 5.3% monthly dividend yield. To achieve $500 in monthly income, an investment of approximately $111,851 (for 1,850 shares) would be required. The company boasts a long history of consistent dividend payments, a vast property portfolio including major national retailers, and high occupancy rates, although some analysts prioritize growth over income.
Global-e Online (NASDAQ:GLBE) Raised to "Buy" at Wall Street Zen
Global-e Online (NASDAQ:GLBE) received an upgrade from "hold" to "buy" by Wall Street Zen, contributing to a "Moderate Buy" consensus rating from analysts with an average target price of $47.80. Despite some recent insider selling totaling $1.43 million, institutional ownership remains high at 94.6%, with several funds increasing their positions. The company, which specializes in cross-border e-commerce solutions, maintains a market capitalization of $4.91 billion and a P/E ratio of 78.19.
Cencora, Inc. $COR Shares Sold by Waycross Partners LLC
Waycross Partners LLC reduced its holdings in Cencora (NYSE:COR) by 33.3% in Q4 2025, selling 5,000 shares and now owning 10,000 shares valued at $3.38 million. Concurrently, CEO Robert P. Mauch sold 5,096 shares for $1.81 million, decreasing his ownership by 7.1%. Despite this, analysts largely maintain bullish ratings with an average target price of $403.17, significantly above the current share price near $312.
Walgreens, Wells Fargo among major companies to report layoffs in Illinois
Several major companies, including Walgreens, Wells Fargo, H&M, Trelleborg, Treehouse Private Brands, Panera, and First Brands Group, announced significant layoffs and facility closures in Illinois during February, impacting thousands of workers across various sectors. These announcements were made under the Illinois Worker Adjustment and Retraining Notification (WARN) Act. While most involve job losses due to restructuring or closures, one case involving Franciscan Health transitioning to Prime Healthcare represents a change in employment entity rather than actual layoffs, with Prime Healthcare planning to offer positions to most current staff.
FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take Down. What’s Next?
The FDA and Novo Nordisk have significantly escalated their enforcement actions against compounded GLP-1 weight-loss drugs and their marketers. This surge in action includes warning letters to online sellers of compounded GLP-1 medications, FDA restrictions on active pharmaceutical ingredients, and a lawsuit by Novo Nordisk against Hims & Hers for patent infringement and promotion of potentially unsafe compounded products. This crackdown follows the launch of Novo Nordisk's new FDA-approved semaglutide tablet and the introduction of lower-cost GLP-1 options via services like TrumpRx.
Ulta Beauty Inc. stock climbs midday amid stable consumer demand signals on NASDAQ
Ulta Beauty Inc. (NASDAQ: ULTA) stock rose midday on Wednesday, reflecting investor confidence in the beauty retailer's operational strength and robust sales growth. This performance is fueled by strong earnings, including an 11.78% year-over-year revenue increase, and the company's defensive position in consumer discretionary spending. Ulta Beauty's ability to maintain strong fundamentals, manage inventory efficiently, and foster loyal customer traffic positions it as a key stock for US investors tracking consumer trends.
CVS Caremark nears settlement with FTC as federal regulators target insulin pricing practices
CVS Caremark is nearing a settlement with the Federal Trade Commission (FTC) regarding its insulin pricing practices. The FTC had previously accused "Big 3 PBMs" of influencing drugmakers to increase prices through a "rebate-chasing" scheme. This potential settlement comes as federal regulators continue to scrutinize the operations of pharmacy benefit managers like CVS Caremark.
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price
Deutsche Bank Aktiengesellschaft has increased its price target for Sutro Biopharma (NASDAQ:STRO) from $51 to $55, maintaining a "buy" rating, which suggests a significant upside of nearly 129%. This positive outlook comes despite Sutro Biopharma reporting a larger-than-expected EPS loss in Q4/FY2025, though revenue surpassed estimates. The company anticipates a near-term clinical catalyst with initial data from the STRO-004 Phase 1 trial expected in mid-2026, which could substantially impact the stock.
Wealth Enhancement Advisory Services LLC Has $35.20 Million Stock Holdings in CVS Health Corporation $CVS
Wealth Enhancement Advisory Services LLC increased its stake in CVS Health Corporation by 10.0%, now holding 436,076 shares valued at $35.20 million. This comes as CVS reported strong quarterly earnings, surpassing analyst expectations, and declared a quarterly dividend of $0.665. The article also details other institutional investors adjusting their holdings and provides an overview of analyst ratings and the company's financial performance.
Wealth Enhancement Advisory Services LLC Raises Holdings in Johnson & Johnson $JNJ
Wealth Enhancement Advisory Services LLC increased its stake in Johnson & Johnson (JNJ) by 5.0% in Q4, making it their 29th-largest holding with 1,936,788 shares valued at approximately $396.8 million. Several analysts have raised their price targets for JNJ, contributing to a consensus "Moderate Buy" rating and a target price of $236.91. Insider selling also occurred, with executives selling shares worth $7.36 million in the last quarter, while the company continues to pay a quarterly dividend of $1.30.
McKesson Corporation stock faces margin pressure amid opioid settlement costs and distribution shift
McKesson Corporation, a major U.S. drug distributor, is navigating significant opioid settlement costs while strategically expanding into higher-margin areas like oncology and specialty medical supplies. The company aims to balance its defensive healthcare exposure with growth opportunities despite generic drug pricing volatility and ongoing litigation. McKesson's U.S. Pharmaceutical division maintains stable revenue, with increasing focus on supply chain resilience and technology integration to enhance efficiency and capitalize on value-based care models.
Top 5 Stocks Under $5 That Could Triple
This article highlights Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) as a top stock under $5 with potential to triple, according to analysts. Wedbush reiterated an "Outperform" rating and raised its price target to $14 due to optimism about the company's precision oncology pipeline, particularly the silevertinib program. Black Diamond Therapeutics recently reported strong Q4 and full-year 2025 financial results and clinical data, with future data readouts and a new Phase 2 trial expected as key catalysts.
CVS Health MinuteClinic Services Expand Access to Affordable Primary Care Across US in 2026
CVS Health's MinuteClinic network is expanding its reach, now with over 1,000 locations nationwide, to offer accessible and affordable primary care services. This expansion addresses the rising costs of healthcare and provider shortages, making essential health services available without appointments and contributing to CVS Health's growth in the integrated care market. The company plans further expansion with 200 new MinuteClinics by 2027 and is leveraging technology and partnerships to enhance its offerings and market position.
Enlivex secures $21M debt financing, buys more RAIN tokens
Enlivex Ltd. has secured $21 million in debt financing and purchased over 3 billion RAIN tokens at a significant discount, while also extending an option to acquire more. The company also announced a share repurchase program and is advancing its Allocetra immunotherapy, despite its stock appearing overvalued by some analysts.
Kirkland’s confirms April shutdown with ‘everything must go’ sale as national retailer pulls the plug on shop
Kirkland's is closing its Rochester, Minnesota store on April 13, with an "Everything Must Go" sale currently underway. This closure comes despite many Kirkland's stores being slated for conversion into smaller Bed Bath & Beyond Home stores following an acquisition by The Brand House Collective. The plan is to convert nearly all Kirkland's stores over the next two years, with the merger aiming for operational efficiency and cost savings.
UnitedHealth Group Incorporated $UNH Shares Sold by Seilern Investment Management Ltd
Seilern Investment Management Ltd reduced its stake in UnitedHealth Group (UNH) by 7.7% in Q4 2025, selling 29,784 shares but still holding 355,936 shares valued at $117.5 million, making UNH its second-largest position. Despite UNH beating Q4 EPS expectations and maintaining a quarterly dividend of $2.21, the stock faces mixed market views due to recent downgrades, regulatory scrutiny, and margin pressures. Analysts currently rate UNH as a "Moderate Buy" with a consensus target price of $372.13.
Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information
Synergy CHC Corp. (NASDAQ: SNYR) has announced it will release its financial results for the fourth quarter and full year 2025 on Tuesday, March 31, 2026, before market open. The company will host a conference call on the same day at 9:00 a.m. ET, featuring CEO Jack Ross and CFO Jaime Fickett. A live webcast and replay will be available on Synergy's Investor Relations website.
Enjoy Texas Roadhouse at home with 'stress-free' prime rib Easter meal kit - just pre-order and pick up
Texas Roadhouse is offering "stress-free" prime rib Easter meal kits for pre-order and pick-up at select locations. These kits contain ready-to-roast prime rib, sides, and rolls, designed for easy at-home preparation. Pricing and contents vary by location, with specific details provided for Dothan, Alabama, and Greece, New York.
Nordea Investment Management AB Has $885.25 Million Stock Holdings in McKesson Corporation $MCK
Nordea Investment Management AB slightly reduced its stake in McKesson Corporation by 2% in Q4, but still holds 1.07 million shares valued at $885.25 million. Meanwhile, other major institutions like Norges Bank, AllianceBernstein, and Arrowstreet significantly increased their positions, with institutional investors now owning about 85.07% of the stock. Analysts maintain a generally positive outlook with an average "Moderate Buy" rating and a price target of $960.93, following McKesson's strong quarterly earnings beat and positive FY2026 guidance.
Wyndham Hotels & Resorts (NYSE:WH) Receives Average Recommendation of "Moderate Buy" from Brokerages
Wyndham Hotels & Resorts (NYSE:WH) has received an average "Moderate Buy" rating from fifteen brokerages, with ten analysts issuing buy recommendations and five recommending a hold. The average 12-month price target is approximately $95.15. Despite insiders selling shares worth about $6.4 million recently, insider ownership remains at 2.46%, and institutional investors hold 93.46% of the stock. The company's recent quarterly earnings beat EPS estimates but revenue declined, while the quarterly dividend was increased to $0.43.
If You Invested $1,000 in Scienture Holdings, Inc (SCNX)
This article analyzes the hypothetical returns of a $1,000 investment in Scienture Holdings, Inc (SCNX) over different timeframes, showing significant losses for investors. It highlights the company's focus on specialty pharmaceutical products like Arbli™ and REZENOPY™, its intellectual property strategy, and recent corporate governance and NASDAQ listing issues reflecting its challenging financial performance.
Preferred Bank (NASDAQ:PFBC) Given Consensus Recommendation of "Hold" by Brokerages
Preferred Bank (NASDAQ:PFBC) has received a consensus "Hold" rating from seven brokerages, with an average 1-year price target of $102.00. The bank recently reported an EPS of $2.79, slightly beating estimates, and declared a quarterly dividend of $0.80 per share. Institutional investors have actively traded the stock, with 72.77% owned by hedge funds and other institutional entities.
Groupama Asset Managment Makes New Investment in Cencora, Inc. $COR
Groupama Asset Management has acquired a new stake of 3,919 shares in Cencora, Inc. (NYSE:COR) valued at approximately $1.225 million during the third quarter. This investment is part of a broader trend of institutional buying in Cencora, with several other major firms also increasing their holdings. Analysts maintain a "Moderate Buy" rating for Cencora, with an average price target of $403.17, following positive earnings results and a declared dividend.
Galecto, Inc. (DMRA) Competitors
This article provides a detailed comparison of Galecto, Inc. (DMRA) with several competitors in the Medical - Pharmaceuticals industry. It analyzes financial metrics such as market capitalization, P/E ratio, and Return on Equity (ROE) for DMRA and its peers. The comparisons also highlight Galecto's volatility relative to other stocks in the sector.
AES (NYSE: AES) proxy outlines 2026 votes and $15.00-per-share cash acquisition
The AES Corporation has filed a definitive proxy statement (Form DEF 14A) for its 2026 virtual annual meeting on April 29, 2026, where stockholders will vote on director elections, executive pay, and auditor ratification, alongside a non-binding proposal about special meeting calls. Concurrently, AES highlights a definitive agreement for Horizon Parent, L.P. to acquire AES for $15.00 per share in cash, valuing the equity at approximately $10.7 billion. This acquisition is subject to stockholder and regulatory approvals, with closing anticipated in late 2026 or early 2027, which would result in AES no longer being a public company.
Swiss Life Asset Management Ltd Buys 7,905 Shares of Cencora, Inc. $COR
Swiss Life Asset Management Ltd increased its stake in Cencora, Inc. (NYSE:COR) by 15.9% in the third quarter, acquiring 7,905 additional shares to bring its total holdings to 57,585 shares valued at $17.997 million. Cencora has a "Moderate Buy" consensus rating from analysts with an average price target of $403.17. The company recently reported Q results with EPS of $4.08, exceeding analyst estimates, and declared a $0.60 quarterly dividend.
